SUSMED, Inc. Faces Downgrade Amid Mixed Technical Indicators and Profitability Concerns
SUSMED, Inc. has transitioned from a 'Not Rated' status to a 'Sell' designation by MarketsMojo, reflecting a change in its technical score. The company's mixed technical indicators and long-term fundamentals reveal challenges, including low profitability and negative EBITDA, despite some positive year-over-year returns.
SUSMED, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment, transitioning from a 'Not Rated' status to a 'Sell' designation by MarketsMOJO. This revision reflects a notable shift in the stock's technical score, which has moved from a bullish outlook to a mildly bullish stance.The technical indicators present a mixed picture. The MACD shows a mildly bearish trend on a weekly basis, while the monthly perspective leans towards a mildly bullish outlook. The Relative Strength Index (RSI) remains neutral for both weekly and monthly assessments. Bollinger Bands indicate a bullish trend on a weekly basis and a mildly bullish trend monthly. Daily moving averages suggest a bullish sentiment, yet the KST presents a mildly bearish view weekly, contrasting with a bullish monthly trend.
Long-term fundamentals reveal challenges, particularly with a low average Return on Equity (ROE) of 0.04%, indicating limited profitability relative to shareholder funds. Additionally, the company is facing risks associated with negative EBITDA, despite a year-over-year return of 52.89% and a profit increase of 21.3%.
For more insights, Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Most Read
